Bone marrow infiltrated natural killer cells predicted the anti-leukemia activity of MCL1 or BCL2 inhibitors in acute myeloid leukemia
Abstract Acute myeloid leukemia (AML) is still incurable due to its heterogeneity and complexity of tumor microenvironment. It is imperative therefore to understand the molecular pathogenesis of AML and identify leukemia-associated biomarkers to formulate effective treatment strategies. Here, we sys...
Main Authors: | Yu-Jun Dai, Si-Yuan He, Fang Hu, Xue-Ping Li, Jian-Ming Zhang, Si-Liang Chen, Wei-Na Zhang, Hai-Min Sun, Da-Wei Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | Molecular Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12943-020-01302-6 |
Similar Items
-
Pharmaceutical Drug Metformin and MCL1 Inhibitor S63845 Exhibit Anticancer Activity in Myeloid Leukemia Cells via Redox Remodeling
by: Giedrė Valiulienė, et al.
Published: (2021-04-01) -
Unraveling the Role of Innate Lymphoid Cells in AcuteMyeloid Leukemia
by: Matthew R. Lordo, et al.
Published: (2021-01-01) -
DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors
by: Yangling Li, et al.
Published: (2020-05-01) -
Targeting MCL-1 in cancer: current status and perspectives
by: Haolan Wang, et al.
Published: (2021-04-01) -
Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy?
by: Kulsoom B, et al.
Published: (2018-03-01)